<DOC>
	<DOC>NCT00718562</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of nilotinib in gastrointestinal stromal tumors patients who failed imatinib and sunitinib therapy.</brief_summary>
	<brief_title>Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib At least one measurable site of disease on CT/MRI scan PS≤2 Normal organ, electrolyte, and bone marrow function Previous treatment with nilotinib or any other drug in this class or other targeted therapy Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry Impaired cardiac function Use of coumarin derivatives (i.e. warfarin) Women who are pregnant or lactating Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sunitinib malate</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Tyrosine</keyword>
</DOC>